AIDS Advocacy Group Sues Trump Administration Over Undisclosed Gilead Agreement
Berlin, Germany — In a legal challenge that could reshape public access to critical HIV prevention drugs, the advocacy group PrEP4All has filed a lawsuit against the Trump administration, alleging the government failed to disclose key details of a research and development agreement with pharmaceutical giant Gilead Sciences. The lawsuit, filed in the U.S. District Court for the Southern District of New York on April 27, 2026, centers on a settlement reached earlier this year that resolved a long-standing patent dispute between the U.S. Government and Gilead over two of the company’s HIV prevention medications, Truvada and Descovy.
The case raises urgent questions about transparency in public-private partnerships, the role of taxpayer-funded research in drug development, and the equitable pricing of life-saving medications. At its core, the lawsuit demands the release of an agreement that PrEP4All argues was central to the January 2025 settlement but has remained shrouded in secrecy, leaving public health advocates and policymakers in the dark about its terms and implications.
The Patent Dispute: A Six-Year Battle Over Publicly Funded Research
The origins of the lawsuit trace back to November 2019, when the U.S. Department of Health and Human Services (HHS), under the Trump administration, filed a lawsuit against Gilead Sciences, alleging the company had infringed on patents held by the Centers for Disease Control and Prevention (CDC). The patents in question covered the apply of antiretroviral drugs for pre-exposure prophylaxis (PrEP), a highly effective HIV prevention strategy that reduces the risk of infection by more than 99% when taken as prescribed, according to the CDC.
The HHS lawsuit claimed that Gilead had built its blockbuster PrEP drugs—Truvada, approved in 2012, and Descovy, approved in 2019—on research funded by U.S. Taxpayers. Specifically, the government alleged that CDC scientists had played a pivotal role in identifying the potential of tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC), the active ingredients in Truvada, for HIV prevention. This research, conducted in collaboration with academic institutions, formed the basis for Gilead’s later commercialization of the drugs.
In court filings, the Trump administration accused Gilead of “exaggerating its own role” in the development of PrEP whereas “ignoring the contributions of CDC scientists.” The government also alleged that Gilead had reaped “hundreds of millions of dollars” from the drugs without compensating the public for its foundational research. At the time, Truvada carried a list price of $21,388 per patient per year in the United States, a cost that advocates argued put the medication out of reach for many at-risk individuals, particularly in low- and middle-income countries.
The 2025 Settlement: A Resolution Without Transparency
The legal battle reached a turning point in January 2025, when the Trump administration announced a settlement with Gilead. The terms of the agreement were not made public, but the administration described it as a resolution that would “ensure broader access to HIV prevention medications while acknowledging the contributions of U.S. Government-funded research.” Although, the lack of transparency around the settlement terms—particularly regarding the role of a separate research and development agreement—has now turn into the focal point of PrEP4All’s lawsuit.
In its complaint, PrEP4All argues that the Trump administration violated the Freedom of Information Act (FOIA) by refusing to disclose the full details of the agreement with Gilead. The group contends that the public has a right to know how the settlement addresses issues of affordability, licensing, and the government’s role in future drug development. “This agreement could have far-reaching implications for how taxpayer-funded research is commercialized,” said Peter Staley, a longtime AIDS activist and founding member of PrEP4All, in a statement. “Without transparency, we cannot ensure that the public’s interests are being protected.”
Why the Lawsuit Matters: Public Health and Drug Pricing at Stake
The legal battle over Gilead’s PrEP drugs is not just about patents—This proves about the broader issue of drug pricing and the role of public investment in pharmaceutical innovation. Truvada and Descovy have been transformative in the fight against HIV, with the CDC estimating that 1.2 million people in the U.S. Alone are at high risk for HIV and could benefit from PrEP. However, the high cost of the medications has been a persistent barrier to access.
In 2021, Gilead faced widespread criticism from advocacy groups, including PrEP4All, for its pricing strategy. The company had initially offered a generic version of Truvada at a reduced price, but critics argued that the move was insufficient to address the needs of uninsured and underinsured populations. The settlement in 2025 was expected to include provisions for broader access, but without transparency, advocates say they cannot verify whether those promises have been kept.
The lawsuit also comes at a time of heightened scrutiny over the Trump administration’s handling of public health initiatives. In September 2025, the administration announced a partnership with Gilead and The Global Fund to Fight AIDS, Tuberculosis and Malaria to distribute Descovy to up to 2 million people in low- and middle-income countries through the President’s Emergency Plan for AIDS Relief (PEPFAR). While the initiative was hailed as a step forward in global HIV prevention, critics questioned whether the administration had secured the best possible terms for taxpayers and patients.
The Broader Implications: Who Owns Publicly Funded Research?
The case against the Trump administration touches on a fundamental question in biomedical research: Who should benefit from discoveries funded by taxpayers? The U.S. Government invests billions of dollars annually in scientific research through agencies like the National Institutes of Health (NIH) and the CDC. When that research leads to commercial products, the public often pays twice—first through taxes, and then through high drug prices.
This issue is not unique to Gilead or HIV prevention. In recent years, similar disputes have arisen over drugs for cancer, hepatitis C, and COVID-19, where public funding played a critical role in development. Advocates argue that greater transparency in government agreements with pharmaceutical companies is essential to ensuring that public investments translate into affordable, accessible medications.
“The public has a right to know how their tax dollars are being used to shape the market for life-saving drugs,” said Dr. James Krellenstein, co-founder of PrEP4All and a plaintiff in the lawsuit. “If the government is entering into agreements that limit competition or keep prices high, we need to see those terms.”
What Happens Next: Legal and Public Health Ramifications
The Trump administration has not yet responded publicly to the lawsuit, but legal experts say the case could set a precedent for how government agencies handle settlements involving publicly funded research. If PrEP4All succeeds, it could force the disclosure of similar agreements in other high-profile drug pricing disputes, potentially reshaping the landscape of pharmaceutical innovation and access.
For now, the next key date in the case is May 20, 2026, when the court is expected to hold a preliminary hearing on PrEP4All’s motion for a temporary restraining order to compel the immediate release of the disputed agreement. In the meantime, advocacy groups are calling on the administration to voluntarily disclose the terms of the settlement, arguing that transparency is critical to rebuilding public trust in government-led public health initiatives.
As the legal battle unfolds, the stakes could not be higher for the millions of people worldwide who rely on PrEP to protect themselves from HIV. The outcome of this case may determine whether taxpayer-funded research continues to fuel high drug prices—or whether it can be leveraged to create a more equitable and accessible healthcare system.
Key Takeaways
- Lawsuit Filed: PrEP4All has sued the Trump administration for failing to disclose details of a research and development agreement with Gilead Sciences, which was central to a January 2025 settlement over HIV prevention drug patents.
- Patent Dispute Origins: The U.S. Government, via the CDC, alleged in 2019 that Gilead infringed on patents for PrEP drugs Truvada and Descovy, which were developed using taxpayer-funded research.
- Settlement Terms Unknown: The 2025 settlement resolved the patent dispute, but its terms—including any provisions for drug pricing or licensing—remain undisclosed, prompting the current lawsuit.
- Public Health Impact: The case highlights broader concerns about drug pricing, transparency in public-private partnerships, and the equitable distribution of life-saving medications.
- Next Steps: A preliminary hearing is scheduled for May 20, 2026, where the court will consider PrEP4All’s request for the immediate release of the disputed agreement.
Frequently Asked Questions
What is PrEP, and why is it important?
PrEP, or pre-exposure prophylaxis, is a medication that reduces the risk of HIV infection by more than 99% when taken as prescribed. It is a critical tool in the global effort to end the HIV epidemic, particularly for populations at high risk of infection, such as men who have sex with men, transgender individuals, and people who inject drugs. The CDC estimates that 1.2 million people in the U.S. could benefit from PrEP.
What are Truvada and Descovy?
Truvada and Descovy are brand-name PrEP medications manufactured by Gilead Sciences. Truvada was approved by the U.S. Food and Drug Administration (FDA) in 2012, while Descovy was approved in 2019. Both drugs contain a combination of antiretroviral medications (tenofovir and emtricitabine) that prevent HIV from replicating in the body. Descovy is marketed as having fewer side effects related to kidney and bone health compared to Truvada.
Why did the U.S. Government sue Gilead?
The U.S. Government, through the Department of Health and Human Services (HHS), sued Gilead in 2019 for patent infringement. The lawsuit alleged that Gilead had built its PrEP drugs on research funded by the CDC and other public institutions but had refused to acknowledge the government’s contributions or enter into a licensing agreement. The government claimed that Gilead had reaped “hundreds of millions of dollars” from the drugs without compensating the public for its foundational research.
What was the 2025 settlement about?
The January 2025 settlement resolved the patent dispute between the Trump administration and Gilead. While the terms of the settlement were not made public, the administration described it as a resolution that would “ensure broader access to HIV prevention medications.” However, the lack of transparency around the agreement—particularly regarding a separate research and development deal—has led to the current lawsuit by PrEP4All.
What does PrEP4All want?
PrEP4All is demanding the full disclosure of the research and development agreement between the Trump administration and Gilead. The group argues that the public has a right to know how the settlement addresses issues of drug pricing, licensing, and the government’s role in future drug development. The lawsuit is filed under the Freedom of Information Act (FOIA), which requires federal agencies to release information requested by the public unless it falls under specific exemptions.
How does this affect global HIV prevention efforts?
The lawsuit comes at a time when the Trump administration has also partnered with Gilead and The Global Fund to distribute Descovy to up to 2 million people in low- and middle-income countries through the PEPFAR program. While the initiative is aimed at expanding access to HIV prevention, critics argue that the lack of transparency in the U.S. Settlement could undermine efforts to negotiate fair pricing and licensing terms for global distribution.
As the legal process moves forward, the outcome of this case could have ripple effects across the pharmaceutical industry, influencing how future disputes over publicly funded research are resolved—and whether the public’s investment in science translates into affordable, accessible healthcare for all.
For readers seeking official updates on the case, court filings and related documents can be accessed through the U.S. Courts’ PACER system. Advocacy groups like PrEP4All also provide ongoing analysis and resources on their website.
What are your thoughts on the balance between public investment in drug development and private sector innovation? Share your views in the comments below, and don’t forget to share this article to keep the conversation going.